Takeaways: The availability of a nasal spray should broaden the addressable market for emergency epinephrine by reducing needle anxiety and administration hesitation, potentially increasing carr...
Takeaways: The decision should expand use of Keytruda plus enfortumab vedotin in the perioperative setting by giving oncologists a data-backed option that improves event-free...
Takeaways: If governments adopt the CDA-AMC recommendation, Ubrelvy could gain public coverage and expand AbbVie’s migraine footprint in Canada, creating a stronger commercial path for...
Takeaways: The decision is especially meaningful for CELYSTRA because Québec is a high-prevalence region for FCS among French Canadians, so public coverage can quickly translate into concentrate...
Takeaways: The decision strengthens Pfizer’s foothold in Canada’s publicly funded pediatric pneumococcal market by making Prevnar 20 the standard for infants in two large provinces, wh...
Takeaways: Rhapsido gives Canadian clinicians a first-in-class, oral BTK inhibitor option for CSU patients who are still symptomatic on H1 antihistamines, adding a targeted,...
Takeaways: Health Canada’s go‑ahead for Devonian’s seamless Phase II/III pediatric Thykamine program positions the company to enter a crowded but fast‑growing non‑steroidal topica...
Takeaways: Aspen-Semaglutide’s approval introduces the generic Ozempic-equivalent into Canada’s GLP‑1 space, setting up price competition and broader access in type 2 diabetes once API supply co...
Takeaways: Leqembi’s positive reimbursement step in Canada is a meaningful commercial win because it could unlock public coverage for the first disease-modifying Alzheimer’s therapy in the count...
Takeaways Médunik Canada’s exclusive distribution of Increlex (mecasermin) with ESTEVE ensures that children and adolescents with severe primary IGF‑1 deficiency in Canada can con...
